Clinical advancements in the field of urology are featured in the news media every day. This section provides patients and physicians with the most up-to-date information on recent urologic advancements around the world.
* Please Note - TUCC does not necessarily advocate any of the treatment methods listed in the articles below. This news feed is provided as a resource for those interested in the latest urologic research occurring around the world.
A prostate-specific antigen cut point of ≥0.4 ng/mL predicts future disease progression, according to a study published in The Journal of Urology.
The past five years have seen a torrent of innovation in the treatment of cancer. More than 70 new drugs have come to market, and for some of these describing their consequences as revolutionary is not hyperbole—at least for those patients lucky enough to respond to them. A diagnosis of advanced melanoma, for example, was once tantamount to a death warrant. Median life expectancy after such news was six to nine months. But recently developed “immuno-oncology” drugs, which exploit a patient’s immune system to fight his tumours, are so effective that, in around a fifth of cases, there is real debate among experts as to whether the patient has actually been cured.
A study on non-coding RNA (Ribonucleic Acid) from prostate cancer patients has identified a series of new prostate cancer markers which can be found in urine. Combining these RNA markers into a single test potentially opens the door for simple, accurate non-invasive testing for prostate cancer. This work is presented at the European Association of Urology Congress in Munich.
In March, the Centers for Medicare and Medicaid Services temporarily suspended the development of a proposed “Non-Recommended Prostate-Specific Antigen (PSA)–Based Screening” measure that would discourage PSA screening in all men. The U.S. Preventive Services Task Force (USPSTF) is currently in the process of updating its recommendations for prostate-cancer screening. The decisions made by these two organizations are likely to determine the fate of PSA screening in the United States.
Drugs designed to lower cholesterol may turn out to be an effective weapon against prostate cancer, research has shown.
These data demonstrate the development and clinical utility of a novel liposomal formulation for the treatment of prostate cancer.
Understanding the complexity of cancer is a major goal of the scientific community, and for kidney cancer researchers this goal just got closer.
Although the association between higher hospital volume and improved outcomes has been well-documented in surgery, there is little data about whether this effect exists for radiation-treated patients. This study investigated whether treatment at a radiation facility that treats a high volume of prostate cancer patients is associated with improved survival for men with high-risk prostate cancer.
As men age, they lose testosterone — which some say affects their sense of well-being and sexual function. But for healthy older men, using supplemental testosterone as a remedy has been controversial. Past studies of the supplement's use have been relatively small, and the evidence about benefits and risks has been mixed.
Now a well-designed study published online Wednesday, in the New England Journal of Medicine, confirms certain benefits in sexual function and mood for some men 65 and over, at least in the first year. Though the gains were modest, and some tended to wane in the latter months of treatment, researchers say the findings are encouraging, and merit further research.
Investigators have created a DNA damage and repair (DDR) pathway profiling method that may be used in the management of patients with high-risk prostate cancer, according to an article published in JAMA Oncology.
TUCC is contracted with all major insurance companies. We look forward to providing you with clinically advanced, compassionate urologic care.